Skip to content
CNCB News
International News Portal 18 November 2026 Headlines from established publishers
World

Alzheimer’s blood marker could predict cognitive decline risks, says Mayo Clinic

A Mayo Clinic study finds a p-tau217 blood test may predict cognitive decline risk within five to 10 years, offering a less invasive option than PET scans.

Alzheimer’s blood marker could predict cognitive decline risks, says Mayo Clinic

A blood test that detects a protein linked to Alzheimer’s disease could help predict whether older adults will develop cognitive decline within five to 10 years, according to a new Mayo Clinic study published in JAMA Neurology.

The study looked at levels of phosphorylated tau 217 (p-tau217) in 2,178 cognitively unimpaired adults, ranging in age from 60 to 90. It also considered age, gender and whether participants carried the APOE ε4 genetic variant, which is associated with Alzheimer’s risk.

The participants – drawn from the Mayo Clinic Study of Aging and the Alzheimer's Disease Neuroimaging Initiative – underwent blood biomarker testing, genetic testing and multiple cognitive assessments.

ALZHEIMER'S WARNING SIGNS COULD EMERGE YEARS BEFORE MEMORY LOSS, STUDY FINDS

While APOE ε4 had a modest association with risk after accounting for p-tau217, older age was associated with greater risk, according to the researchers.

For example, at the same elevated p-tau217 level, a 65-year-old faced a 6% estimated five-year risk of mild cognitive impairment, compared to a 37% risk for an 85-year-old.

Alzheimer’s disease is marked by plaques and tangles that accumulate in the brain, noted senior author Clifford Jack Jr., M.D., a Mayo Clinic neuroradiologist.

"The test tells you, just by taking a blood sample, whether someone has that pathology in the brain," he told Fox News Digital, adding that higher levels of the pathology are associated with a greater risk of progressing from normal cognition to impairment.

10 HEALTH CONDITIONS MAY BE LINKED TO ALZHEIMER'S YEARS BEFORE DIAGNOSIS

Detecting p-tau217 in blood may be "less invasive and potentially more scalable" than using PET scans to measure amyloid burden, a hallmark of Alzheimer’s disease that is associated with future cognitive impairment.

"The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology," said first author Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher, in a news release.

If investigational treatments are found to be effective at preventing or delaying cognitive decline, this blood test could take on greater significance, according to the researchers.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment," Jack noted.

The risk estimates were developed in the Mayo Clinic Study of Aging, which is drawn from a specific geographical area.

"The older population in southeast Minnesota is not representative of the entire United States," Jack said.

CLICK HERE FOR MORE HEALTH STORIES

While the study’s methods could be applied in other populations, the researcher said the findings need to be replicated outside the region.

The risk prediction model is not yet ready for routine screening of people without cognitive symptoms, according to the research team.

"There is no treatment that’s been approved for people who are [asymptomatic] but have the disease in the brain," Jack told Fox News Digital. "Therefore, there’s no reason to do the test. … The results of the test would not change your medical management at all since there’s no treatment available."

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

That could change if preventive treatments are approved, he added.

The study does not establish that routine blood testing prevents dementia or improves clinical outcomes.

"Many elderly people who have the pathology in the brain at lower levels will never develop symptoms in their lifetime," Jack added, noting that some people with Alzheimer’s-related pathology may also die of another cause before developing cognitive impairment.

This story was first published by Fox News - Latest. Read the original report